A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.

A Arason, A Jonasdottir, R B Barkardottir, J T Bergthorsson, M D Teare, D F Easton, V Egilsson

Department of Pathology, University Hospital of Iceland, Reykjavik.

The majority of breast cancer in high risk families is believed to result from a mutation in either of two genes named BRCA1 and BRCA2. A germline defect in either gene is usually followed by chromosomal deletion of the normal allele in the tumour. In Iceland two recurrent mutations have been identified, 999del5 BRCA2 and G5193A BRCA1. In this study, randomly selected pairs of sisters diagnosed with breast cancer at the age of 60 years or younger were analysed to evaluate the proportion of breast cancer resulting from BRCA1 and BRCA2. Genotypes and allele loss in tumour tissue from 42 sister pairs were compared using markers within and around the BRCA1 and BRCA2 genes. Eleven sister pairs were highly suggestive of BRCA2 linkage, and no obvious BRCA1 linkage was seen. Screening for the G5193A BRCA1 and 999del5 BRCA2 mutations showed the 999del5 mutation in the 11 BRCA2 suggestive pairs plus three pairs less indicative of linkage, and the G5193A BRCA1 mutation in one pair. When known mutation carriers are removed from the group, no indication of further linkage to BRCA1 or BRCA2 is seen. The results of our studies suggest that a large proportion of familial breast cancer in Iceland is the result of the 999del5 BRCA2 mutation, and it is unlikely that BRCA1 and BRCA2 germline mutations other than 999del5 and G5193A play a significant role in hereditary breast cancer in Iceland. Furthermore it can be concluded that most families with BRCA1 or BRCA2 linkage are easily identified by studying LOH around the defective gene in as few as two affected relatives.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Nelson, H. D., Huffman, L. H., Fu, R., Harris, E. L. (2005). Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force. ANN INTERN MED 143: 362-379 [Abstract] [Full Text]  
• Tulinius, H, Olafsdottir, G H, Sigvaldason, H, Arason, A, Barkardottir, R B, Egilsson, V, Ogmundsdottir, H M, Tryggvadottir, L, Gudlaugsdottir, S, Eyfjord, J E (2002). The effect of a single BRCA2 mutation on cancer in Iceland. J. Med. Genet. 39: 457-462 [Abstract] [Full Text]  
• Shih, H. A., Couch, F. J., Nathanson, K. L., Blackwood, M. A., Rebbeck, T. R., Armstrong, K. A., Calzone, K., Stopfer, J., Seal, S., Stratton, M. R., Weber, B. L. (2002). BRCA1 and BRCA2 Mutation Frequency in Women Evaluated in a Breast Cancer Risk Evaluation Clinic. JCO 20: 994-999 [Abstract] [Full Text]  
• DAVIES, J F, REDMOND, E K, COX, M C, LALLOO, F I, ELLES, R, EVANS, D G R (2000). 2157delG: a frequent mutation in BRCA2 missed by PTT. J. Med. Genet. 37: 42e-42 [Full Text]